(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Iran, Hezbollah fire rockets at Israel during Passover celebrations - 2German state railway loss widens, passengers warned of trouble ahead
- 3Unwinding History's Secrets: Looking for the Response to Antiquated Human advancements
- 4Warming winters lead to more nitrate pollution in the drinking water near farms
- 5Canada cancels its 1st moon rover: 'It's hopefully not a lost cause'
- More people are addicted to marijuana, but fewer of them are seeking help, experts say
- Picking the Right Home Machines: A Commonsense Aide
- Ways to track down the Right Criminal Legal counselor
- Instructions to Upgrade the Security Elements of Your Kona SUV
- 1st results from Blue Ghost lunar lander reveal how much we still don't know about the moon
- Mickey Lee of 'Big Brother' fame dead at 35 after flu complications, family says
- Manual for Tracking down the Mysterious Cascades in China
- The Incomparable Advanced cameras: Which One Will Win?
- Sea Ice Hits New Low in Hottest Year on Record for the Arctic
